ReviewThyroid research2025
Prognosis of differentiated thyroid cancer in patients with Graves' disease: a meta-analysis.
Review in Thyroid research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Papillary thyroid carcinoma in graves' disease: prevalence, clinicopathological features, and preoperative predictors.BMC surgery · 2026Article
- Analysis of the impact of Graves' disease on the efficacy of initial radioactive iodine therapy in patients with differentiated thyroid cancer.American journal of cancer research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo methodically evaluate the relationship between the prognosis of individuals with differentiated thyroid carcinoma (DTC) and Graves’ disease (GD).
methodsWe comprehensively searched the databases of PubMed, EMbase, Web of Science and Cochrane Library from inception to April 2025. We included published studies that compared the risk of recurrence/persistence, the risk of mortality and disease-free survival (DFS) between DTC patients with GD and those with non-GD. Two researchers evaluated the quality of the literature eligible for inclusion and extracted the data.
resultsA total of four case-control studies and eleven cohort studies were included (1215 TC patients with GD and 3330 TC patients with non-GD). The meta-analysis suggested that GD might be associated with a higher risk of recurrence/persistence of coexisting DTC (OR 3.39, CI 95% 1.34–8.57 and P = 0.008), especially when the tumor diameter was ≧ 1 cm (OR 5.39 and CI 95% 1.38–21.07, P = 0.038). The risk of mortality was significantly different between the GD group and non-GD group (OR 2.37, CI 95% 1.04–5.39 and P = 0.04), especially when the follow-up time ≧ 10 years (OR = 9.79, CI 95% 2.48–38.72 and P = 0.001). The DFS was not significantly different between the GD group and non-GD group (OR 0.51, CI 95% 0.11–2.32 and P < 0.001).
conclusionGD may be associated with a higher risk of recurrence/persistence of coexisting DTC, and DTC patients with GD had a higher risk of mortality than non-GD, especially when the follow-up time was more than 10 years. Due to the substantial heterogeneity and insufficient event data, it is difficult to draw a definitive conclusion regarding a potential increased risk of DTC recurrence/persistence in GD patients with the tumor diameter was ≥ 1 cm, whereas the clinical outcome of small thyroid cancer (the tumor diameter < 1 cm) is not related to the presence/absence of GD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.